Autologous Stem Cell Transplantation Outcomes in Patients With Peripheral T-Cell Lymphomas
Patients with higher International Prognostic Index scores or advanced-stage disease experienced improved survival when treated with ASCT.
News
Follicular Lymphoma With Extranodal Disease Only: When to Suspect Systemic Disease
A case study of a patient with persistent skin lesions illustrates some of the challenges involved in diagnosing follicular lymphoma presenting with extranodal disease only.
Chemotherapy-Free Combo Therapy Approved for Previously Untreated CLL
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Mirvetuximab Soravtansine Data Lacking for FDA’s Accelerated Approval in Ovarian CA
The Food and Drug Administration (FDA) has recommended that ImmunoGen, Inc. conduct a new phase 3 randomized trial to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) in patients with high folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.
Extranodal and Spleen Involvement Predict Outcomes in Follicular Lymphoma
The detection of extranodal, soft tissue, bone, and spleen involvement at baseline predicted poor survival outcomes in patients with untreated follicular lymphoma.
Bavencio Plus Inlyta Approved as First-Line Tx for Advanced Renal Cell Carcinoma
The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Interest Level High, but Knowledge Low Regarding Music-Based Therapeutic Options
A survey study sought to determine levels of knowledge and interest among oncology and palliative care nurses regarding music therapy/care.
Relapse Risk in Pediatric Acute Myeloid Leukemia With Granulocyte Colony-Stimulating Factor
Relapse risk increased with cumulative granulocyte colony-stimulating factor dosage but appeared to level out at approximately 75 mg/kg to 100 mg/kg.
Cyramza Approved to Treat Hepatocellular Carcinoma
The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.
Imaging Studies Critical in Distinguishing Extramedullary Disease in Multiple Myeloma Diagnosis
This case illustrates the role of PET/CT imaging at diagnosis in determining extramedullary disease in patients with multiple myeloma.
Kaposi Sarcoma Treatment Gets Breakthrough Therapy Designation
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pomalyst (pomalidomide; Celgene) for the treatment of patients with Kaposi sarcoma.
News Is Good and Bad for Oncology Patient Navigation Studies
A systematic review of studies had surprising findings on the efficacy of oncology patient navigation.
Darolutamide Granted Priority Review Status for nmCRPC
FDA has accepted a New Drug Application and granted Priority Review for darolutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Inclusion of Geriatric Assessments Alters Cancer Management in Older Patients
A prospective cohort study sought to evaluate the impact of including a nurse geriatric assessment and input from an OMT in treatment decision-making for older patients with cancer.
Incorporating Distress Screening Improves Referrals in Telephonic Case Management for Cancer Patients
This study validated the effectiveness of the NCCN Distress Thermometer and Problem List for Patients, validated tools for assessing distress in patients with cancer, for use in telephonic case management.
ASTRO Releases Consensus Statement on Improving Prior Authorization
A survey released by ASTRO, an industry trade group representing radiation oncologists, concluded that prior authorization serves as a barrier to prompt and effective patient care.
Risk-Based Breast Cancer Screening Guidelines from the American Society of Breast Cancer Surgeons
These guidelines remove ambiguity regarding screening mammography recommendations for women in their 40s.
Tibsovo Approved to Treat Newly Diagnosed AML With IDH1 Mutation
The FDA has expanded the indication for Tibsovo to include treatment of newly diagnosed acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
FDA Approves New First-Line Treatment for Advanced RCC
FDA approved pembrolizumab, a PD-1 inhibitor, in combination with axitinib, a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma.
Adjuvant Radiation Therapy Beneficial in Advanced UTUC
Radiation therapy administered after surgery for advanced upper tract urothelial carcinoma improves cancer-specific and distant metastasis-free survival, a study found.
Want to read more?
Please login or register first to view this content.
Next post in Web Exclusives
